NASDAQ:AXGN - AxoGen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$42.75 -1.15 (-2.62 %)
(As of 05/23/2018 05:28 AM ET)
Previous Close$43.90
Today's Range$42.40 - $43.90
52-Week Range$14.25 - $46.00
Volume215,408 shs
Average Volume534,837 shs
Market Capitalization$1.52 billion
P/E Ratio-137.90
Dividend YieldN/A
Beta-0.04

About AxoGen (NASDAQ:AXGN)

AxoGen logoAxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800

Debt

Debt-to-Equity Ratio0.82
Current Ratio3.32
Quick Ratio2.81

Price-To-Earnings

Trailing P/E Ratio-137.90
Forward P/E Ratio-112.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$60.43 million
Price / Sales24.55
Cash FlowN/A
Price / CashN/A
Book Value$0.63 per share
Price / Book67.86

Profitability

EPS (Most Recent Fiscal Year)($0.31)
Net Income$-10,440,000.00
Net Margins-18.83%
Return on Equity-61.66%
Return on Assets-21.29%

Miscellaneous

Employees199
Outstanding Shares34,700,000

AxoGen (NASDAQ:AXGN) Frequently Asked Questions

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

How were AxoGen's earnings last quarter?

AxoGen, Inc (NASDAQ:AXGN) posted its earnings results on Monday, April, 30th. The medical equipment provider reported ($0.11) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.11). The medical equipment provider earned $17.30 million during the quarter, compared to the consensus estimate of $17.16 million. AxoGen had a negative return on equity of 61.66% and a negative net margin of 18.83%. The business's quarterly revenue was up 41.8% compared to the same quarter last year. View AxoGen's Earnings History.

What price target have analysts set for AXGN?

8 brokerages have issued 1-year target prices for AxoGen's stock. Their predictions range from $21.00 to $45.00. On average, they expect AxoGen's stock price to reach $35.5714 in the next twelve months. View Analyst Ratings for AxoGen.

Who are some of AxoGen's key competitors?

Who are AxoGen's key executives?

AxoGen's management team includes the folowing people:
  • Ms. Karen Zaderej, Pres, CEO & Director (Age 56)
  • Mr. Peter J. Mariani, CFO & Principal Accounting Officer (Age 54)
  • Mr. Gregory G. Freitag, Gen. Counsel, Sr. VP of Bus. Devel. & Director (Age 56)
  • Mr. Shawn F. McCarrey, Sr. VP of Sales (Age 60)
  • Mr. Jon S. Gingrich, Chief Commercial Officer (Age 49)

Has AxoGen been receiving favorable news coverage?

News headlines about AXGN stock have trended somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AxoGen earned a daily sentiment score of 0.19 on Accern's scale. They also assigned media stories about the medical equipment provider an impact score of 46.21 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are AxoGen's major shareholders?

AxoGen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.94%), Opaleye Management Inc. (4.94%), Wells Fargo & Company MN (2.06%), Rock Springs Capital Management LP (1.46%), Lord Abbett & CO. LLC (1.04%) and Next Century Growth Investors LLC (1.02%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Guido J Neels, James E Flynn, Jamie Mark Grooms, John P Engels, Joseph M Mandato, Karen L Zaderej, Peter J Mariani, Robert James Rudelius and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.

Which major investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including Next Century Growth Investors LLC, Opaleye Management Inc., Russell Investments Group Ltd., Cortina Asset Management LLC, Bamco Inc. NY, Eversept Partners LLC, Timpani Capital Management LLC and Millrace Asset Group Inc.. Company insiders that have sold AxoGen company stock in the last year include Guido J Neels, Jamie Mark Grooms, Robert James Rudelius and Shawn F Mccarrey. View Insider Buying and Selling for AxoGen.

Which major investors are buying AxoGen stock?

AXGN stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., Eagle Asset Management Inc., Atlantic Trust Group LLC, Lord Abbett & CO. LLC, Lisanti Capital Growth LLC, Citadel Advisors LLC and Rock Springs Capital Management LP. Company insiders that have bought AxoGen stock in the last two years include Amy Mcbride Wendell, John P Engels, Karen L Zaderej and Peter J Mariani. View Insider Buying and Selling for AxoGen.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $42.75.

How big of a company is AxoGen?

AxoGen has a market capitalization of $1.52 billion and generates $60.43 million in revenue each year. The medical equipment provider earns $-10,440,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. AxoGen employs 199 workers across the globe.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]


MarketBeat Community Rating for AxoGen (AXGN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  290
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AxoGen (NASDAQ:AXGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for AxoGen in the last 12 months. Their average twelve-month price target is $35.5714, suggesting that the stock has a possible downside of 16.79%. The high price target for AXGN is $45.00 and the low price target for AXGN is $21.00. There are currently 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $35.5714$33.1429$29.3333$24.40
Price Target Upside: 16.79% downside11.97% downside10.07% upside0.41% upside

AxoGen (NASDAQ:AXGN) Consensus Price Target History

Price Target History for AxoGen (NASDAQ:AXGN)

AxoGen (NASDAQ:AXGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Market Outperform$34.00 ➝ $43.00HighView Rating Details
5/1/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$37.00 ➝ $45.00HighView Rating Details
3/19/2018Jefferies GroupBoost Price TargetBuy$45.00MediumView Rating Details
3/2/2018Lake Street CapitalSet Price TargetBuy ➝ Buy$26.00 ➝ $38.00MediumView Rating Details
2/5/2018William BlairInitiated CoverageOutperformHighView Rating Details
11/21/2017Leerink SwannBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $30.00N/AView Rating Details
11/21/2017WedbushReiterated RatingBuy$22.00 ➝ $27.00N/AView Rating Details
9/12/2017Roth CapitalReiterated RatingBuy$18.00 ➝ $21.00LowView Rating Details
(Data available from 5/23/2016 forward)

Earnings

AxoGen (NASDAQ:AXGN) Earnings History and Estimates Chart

Earnings by Quarter for AxoGen (NASDAQ:AXGN)

AxoGen (NASDAQ:AXGN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.23)
2019 EPS Consensus Estimate: ($0.11)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.15)$0.01($0.08)
Q2 20184($0.12)$0.03($0.06)
Q3 20184($0.09)$0.04($0.04)
Q4 20183($0.08)($0.03)($0.06)
Q1 20192($0.07)($0.04)($0.06)
Q2 20192($0.04)($0.03)($0.04)
Q3 20192($0.04)($0.01)($0.03)
Q4 20191$0.01$0.01$0.01

AxoGen (NASDAQ AXGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018Q1 2018($0.11)($0.11)$17.16 million$17.30 millionViewListenView Earnings Details
2/28/2018Q4 2017($0.09)($0.07)$16.38 million$16.97 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.06)($0.06)$15.55 million$16.05 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.08)($0.06)$14.40 million$15.20 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.10)($0.11)$11.83 million$12.24 millionViewListenView Earnings Details
2/22/2017Q4 2016($0.09)($0.10)$11.41 millionViewListenView Earnings Details
11/2/2016Q3 2016($0.08)($0.08)$11.21 million$11.21 millionViewN/AView Earnings Details
8/3/2016Q2($0.12)($0.09)$9.28 million$10.38 millionViewN/AView Earnings Details
5/4/2016Q1 2016($0.13)($0.12)$7.74 million$8.11 millionViewN/AView Earnings Details
2/29/2016Q4 2015($0.11)($0.12)$7.13 million$7.81 millionViewN/AView Earnings Details
11/5/2015Q3 2015($0.12)($0.11)$6.70 million$8.15 millionViewN/AView Earnings Details
8/6/2015Q2 2015($0.15)($0.13)$5.89 million$6.42 millionViewN/AView Earnings Details
5/5/2015Q1 2015($0.17)($0.16)$4.90 million$4.95 millionViewN/AView Earnings Details
3/5/2015Q4 2014($0.18)($0.36)$4.74 million$4.79 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.24)($0.19)$4.67 millionViewN/AView Earnings Details
8/4/2014Q2 2014($0.22)($0.21)$3.30 million$4.21 millionViewN/AView Earnings Details
4/30/2014Q1 2014($0.26)($0.24)$2.75 million$3.14 millionViewN/AView Earnings Details
3/6/2014($0.22)($0.24)$3.17 million$2.99 millionViewN/AView Earnings Details
10/30/2013Q3 2013($0.20)($0.25)$3.07 million$2.96 millionViewN/AView Earnings Details
8/14/2013Q2 2013($0.31)$2.86 million$2.86 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.26)($0.31)$2.53 million$2.14 millionViewN/AView Earnings Details
3/12/2013Q4 2012($0.23)($0.36)ViewN/AView Earnings Details
11/7/2012Q3 2012($0.17)($0.20)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.19)($0.15)ViewN/AView Earnings Details
5/14/2012Q1 2012($0.19)($0.19)ViewN/AView Earnings Details
11/9/2011Q3 2011($2.60)ViewN/AView Earnings Details
8/11/2011Q2 2011$0.06ViewN/AView Earnings Details
5/17/2011Q1 2011$0.21ViewN/AView Earnings Details
3/30/2011Q4 2010($0.09)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.11)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.05)ViewN/AView Earnings Details
5/17/2010Q1 2010($0.06)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AxoGen (NASDAQ:AXGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AxoGen (NASDAQ AXGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.86%
Institutional Ownership Percentage: 71.02%
Insider Trading History for AxoGen (NASDAQ:AXGN)
Institutional Ownership by Quarter for AxoGen (NASDAQ:AXGN)

AxoGen (NASDAQ AXGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/16/2018Shawn F MccarreySVPSell10,000$43.47$434,700.0033,057View SEC Filing  
2/20/2018Jamie Mark GroomsDirectorSell63,395$27.67$1,754,139.655,827View SEC Filing  
2/15/2018Jamie Mark GroomsCFOSell95,712$26.84$2,568,910.08View SEC Filing  
2/13/2018Jamie Mark GroomsCFOSell10,300$26.21$269,963.00View SEC Filing  
12/12/2017Jamie Mark GroomsDirectorSell38,405$26.35$1,011,971.75View SEC Filing  
12/8/2017Jamie Mark GroomsDirectorSell84,295$26.38$2,223,702.10View SEC Filing  
12/6/2017Jamie Mark GroomsDirectorSell21,290$26.22$558,223.80View SEC Filing  
11/20/2017Guido J NeelsDirectorSell1,150,000$19.74$22,701,000.00View SEC Filing  
9/11/2017Robert James RudeliusDirectorSell16,143$18.00$290,574.0043,273View SEC Filing  
10/7/2016Amy Mcbride WendellDirectorBuy13,333$7.50$99,997.5013,333View SEC Filing  
10/7/2016John P EngelsVPBuy4,000$7.50$30,000.0098,425View SEC Filing  
10/7/2016Karen L ZaderejCEOBuy10,000$7.50$75,000.00242,147View SEC Filing  
10/7/2016Peter J MarianiCFOBuy3,333$7.50$24,997.503,333View SEC Filing  
8/9/2016Joseph M MandatoDirectorSell149,618$8.54$1,277,737.72View SEC Filing  
8/8/2016Joseph M MandatoDirectorSell107,450$8.63$927,293.50View SEC Filing  
7/21/2016James E FlynnInsiderSell102,136$6.70$684,311.20View SEC Filing  
7/18/2016James E FlynnInsiderSell279,303$7.53$2,103,151.59View SEC Filing  
9/18/2015James E FlynnInsiderSell345,000$5.50$1,897,500.00View SEC Filing  
6/3/2015Joseph M MandatoDirectorBuy6,500$3.10$20,150.00View SEC Filing  
6/2/2015Lee Robert Johnston JrInsiderBuy5,000$3.06$15,300.00View SEC Filing  
4/8/2015James E FlynnInsiderSell144,385$3.25$469,251.25View SEC Filing  
12/10/2014Lee Robert Johnston JrCFOBuy10,000$3.06$30,600.00View SEC Filing  
8/12/2014Mark Stephen GoldDirectorBuy20,000$2.29$45,800.00View SEC Filing  
8/8/2014Mark Stephen GoldDirectorBuy11,000$2.31$25,410.00View SEC Filing  
6/6/2014Lee Robert Johnston JrCFOBuy10,000$2.58$25,800.00View SEC Filing  
6/3/2014Gregory Gene FreitagCFOBuy5,200$2.45$12,740.00View SEC Filing  
6/3/2014Karen L ZaderejCEOBuy5,000$2.43$12,150.00View SEC Filing  
5/20/2014Jill F SchiaparelliSVPBuy2,000$2.63$5,260.00View SEC Filing  
5/12/2014Karen L ZaderejCEOBuy5,000$2.70$13,500.00View SEC Filing  
5/7/2014Mark Stephen GoldDirectorBuy1,977$2.60$5,140.20View SEC Filing  
3/13/2014Karen L ZaderejCEOBuy1,500$3.49$5,235.00View SEC Filing  
8/29/2013Shawn F MccarreySVPBuy25,000$3.21$80,250.00View SEC Filing  
8/24/2013Shawn F MccarreySVPBuy5,000$3.00$15,000.00View SEC Filing  
8/14/2013Jill F SchiaparelliSVPBuy5,000$3.00$15,000.00View SEC Filing  
8/14/2013John Frederick HarperDirectorBuy66,666$3.00$199,998.00View SEC Filing  
8/14/2013Karen L ZaderejCEOBuy8,334$3.00$25,002.00View SEC Filing  
12/4/2012Jill F SchiaparelliSVPBuy2,000$2.55$5,100.00View SEC Filing  
11/29/2012Jill F SchiaparelliSVPBuy1,000$2.70$2,700.00View SEC Filing  
11/15/2012Jill F SchiaparelliSVPBuy2,750$2.56$7,040.00View SEC Filing  
10/1/2012John Frederick HarperDirectorBuy86,557$3.61$312,470.77View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AxoGen (NASDAQ AXGN) News Headlines

Source:
DateHeadline
Reviewing AxoGen (AXGN) and Biolife Solutions (BLFS)Reviewing AxoGen (AXGN) and Biolife Solutions (BLFS)
www.americanbankingnews.com - May 22 at 1:25 PM
 Brokerages Expect AxoGen, Inc (AXGN) Will Announce Quarterly Sales of $21.07 Million Brokerages Expect AxoGen, Inc (AXGN) Will Announce Quarterly Sales of $21.07 Million
www.americanbankingnews.com - May 22 at 2:14 AM
BRIEF-Axogen, Inc. Announces Appointment Of Karen Zaderej As Chairman Of The BoardBRIEF-Axogen, Inc. Announces Appointment Of Karen Zaderej As Chairman Of The Board
www.reuters.com - May 21 at 9:16 AM
AxoGen, Inc. Announces Appointment of Karen Zaderej as Chairman of the BoardAxoGen, Inc. Announces Appointment of Karen Zaderej as Chairman of the Board
finance.yahoo.com - May 21 at 9:16 AM
AxoGen, Inc (AXGN) Given Average Rating of "Buy" by AnalystsAxoGen, Inc (AXGN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 21 at 8:50 AM
 Analysts Anticipate AxoGen, Inc (AXGN) Will Announce Earnings of -$0.06 Per Share Analysts Anticipate AxoGen, Inc (AXGN) Will Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - May 20 at 9:28 PM
BRIEF-Axogen Inc Says On May 15, Board Elected CEO Zaderej To Succeed Grooms As ChairmanBRIEF-Axogen Inc Says On May 15, Board Elected CEO Zaderej To Succeed Grooms As Chairman
www.reuters.com - May 19 at 9:23 AM
AxoGen, Inc (AXGN) SVP Shawn F. Mccarrey Sells 10,000 SharesAxoGen, Inc (AXGN) SVP Shawn F. Mccarrey Sells 10,000 Shares
www.americanbankingnews.com - May 18 at 7:55 PM
Head to Head Contrast: AxoGen (AXGN) vs. Viveve Medical (VIVE)Head to Head Contrast: AxoGen (AXGN) vs. Viveve Medical (VIVE)
www.americanbankingnews.com - May 17 at 1:31 PM
William Blair Equities Analysts Raise Earnings Estimates for AxoGen, Inc (AXGN)William Blair Equities Analysts Raise Earnings Estimates for AxoGen, Inc (AXGN)
www.americanbankingnews.com - May 16 at 7:26 AM
BRIEF-Axogen Inc Announces Closing Of Public Offering Of Common StockBRIEF-Axogen Inc Announces Closing Of Public Offering Of Common Stock
www.reuters.com - May 15 at 4:48 PM
AxoGen, Inc. Announces Closing of Public Offering of Common StockAxoGen, Inc. Announces Closing of Public Offering of Common Stock
finance.yahoo.com - May 14 at 10:18 AM
AxoGen (AXGN) Prices Upsized 3M Share Offering at $41AxoGen (AXGN) Prices Upsized 3M Share Offering at $41
www.streetinsider.com - May 11 at 10:23 AM
Analyzing CHF Solutions (CHFS) and AxoGen (AXGN)Analyzing CHF Solutions (CHFS) and AxoGen (AXGN)
www.americanbankingnews.com - May 10 at 11:50 AM
BRIEF-AxoGen Upsizes Public Offering To 3 Mln Shares At $41 Per ShareBRIEF-AxoGen Upsizes Public Offering To 3 Mln Shares At $41 Per Share
www.reuters.com - May 9 at 4:31 PM
AxoGen, Inc. Announces Upsizing and Pricing of Public Offering of Common StockAxoGen, Inc. Announces Upsizing and Pricing of Public Offering of Common Stock
finance.yahoo.com - May 9 at 9:30 AM
BRIEF-AxoGen Announces Proposed Public Offering Of Common StockBRIEF-AxoGen Announces Proposed Public Offering Of Common Stock
www.reuters.com - May 8 at 9:23 AM
AxoGen (AXGN) to Offer 2M SharesAxoGen (AXGN) to Offer 2M Shares
www.streetinsider.com - May 8 at 9:23 AM
AxoGen Announces Proposed Public Offering of Common StockAxoGen Announces Proposed Public Offering of Common Stock
finance.yahoo.com - May 7 at 4:37 PM
AxoGen, Inc (AXGN) Expected to Announce Quarterly Sales of $21.07 MillionAxoGen, Inc (AXGN) Expected to Announce Quarterly Sales of $21.07 Million
www.americanbankingnews.com - May 5 at 3:52 AM
AxoGen (AXGN) Upgraded to Strong-Buy by ValuEngineAxoGen (AXGN) Upgraded to Strong-Buy by ValuEngine
www.americanbankingnews.com - May 4 at 12:21 AM
-$0.09 Earnings Per Share Expected for AxoGen, Inc (AXGN) This Quarter-$0.09 Earnings Per Share Expected for AxoGen, Inc (AXGN) This Quarter
www.americanbankingnews.com - May 3 at 5:56 PM
FY2018 EPS Estimates for AxoGen, Inc Lowered by Analyst (AXGN)FY2018 EPS Estimates for AxoGen, Inc Lowered by Analyst (AXGN)
www.americanbankingnews.com - May 3 at 9:52 AM
Jefferies Group Weighs in on AxoGen, Incs Q2 2018 Earnings (AXGN)Jefferies Group Weighs in on AxoGen, Inc's Q2 2018 Earnings (AXGN)
www.americanbankingnews.com - May 3 at 9:01 AM
Q2 2018 EPS Estimates for AxoGen, Inc Decreased by Leerink Swann (AXGN)Q2 2018 EPS Estimates for AxoGen, Inc Decreased by Leerink Swann (AXGN)
www.americanbankingnews.com - May 3 at 9:01 AM
AxoGen, Inc (AXGN) Forecasted to Post Q2 2018 Earnings of ($0.05) Per ShareAxoGen, Inc (AXGN) Forecasted to Post Q2 2018 Earnings of ($0.05) Per Share
www.americanbankingnews.com - May 3 at 9:01 AM
Leerink Swann Analysts Reduce Earnings Estimates for AxoGen, Inc (AXGN)Leerink Swann Analysts Reduce Earnings Estimates for AxoGen, Inc (AXGN)
www.americanbankingnews.com - May 2 at 10:21 AM
Analysts Offer Predictions for AxoGen, Incs FY2019 Earnings (AXGN)Analysts Offer Predictions for AxoGen, Inc's FY2019 Earnings (AXGN)
www.americanbankingnews.com - May 2 at 10:02 AM
AxoGen, Inc. 2018 Q1 - Results - Earnings Call SlidesAxoGen, Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 1 at 4:24 PM
AxoGen (AXGN) Price Target Increased to $43.00 by Analysts at JMP SecuritiesAxoGen (AXGN) Price Target Increased to $43.00 by Analysts at JMP Securities
www.americanbankingnews.com - May 1 at 10:42 AM
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2018 Results - Earnings Call TranscriptAxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 1 at 9:28 AM
Edited Transcript of AXGN earnings conference call or presentation 30-Apr-18 8:30pm GMTEdited Transcript of AXGN earnings conference call or presentation 30-Apr-18 8:30pm GMT
finance.yahoo.com - May 1 at 9:28 AM
AxoGen: 1Q Earnings SnapshotAxoGen: 1Q Earnings Snapshot
finance.yahoo.com - May 1 at 9:28 AM
Cantor Fitzgerald Reaffirms "Overweight" Rating for AxoGen (AXGN)Cantor Fitzgerald Reaffirms "Overweight" Rating for AxoGen (AXGN)
www.americanbankingnews.com - May 1 at 9:08 AM
AxoGen (AXGN) Announces Quarterly  Earnings ResultsAxoGen (AXGN) Announces Quarterly Earnings Results
www.americanbankingnews.com - April 30 at 9:14 PM
AxoGen (AXGN) Misses Q1 EPS by 5cAxoGen (AXGN) Misses Q1 EPS by 5c
www.streetinsider.com - April 30 at 4:26 PM
BRIEF-AxoGen Reports Q1 Loss Per Share Of $0.16BRIEF-AxoGen Reports Q1 Loss Per Share Of $0.16
www.reuters.com - April 30 at 4:26 PM
AxoGen, Inc. Reports 2018 First Quarter Financial ResultsAxoGen, Inc. Reports 2018 First Quarter Financial Results
finance.yahoo.com - April 30 at 4:26 PM
Reviewing AxoGen (AXGN) and The CompetitionReviewing AxoGen (AXGN) and The Competition
www.americanbankingnews.com - April 29 at 7:55 AM
Head to Head Analysis: AxoGen (AXGN) & Its PeersHead to Head Analysis: AxoGen (AXGN) & Its Peers
www.americanbankingnews.com - April 28 at 3:06 AM
AxoGen (AXGN) & Its Peers Head-To-Head ComparisonAxoGen (AXGN) & Its Peers Head-To-Head Comparison
www.americanbankingnews.com - April 28 at 1:20 AM
AxoGen (AXGN) vs. Its Peers Financial AnalysisAxoGen (AXGN) vs. Its Peers Financial Analysis
www.americanbankingnews.com - April 26 at 1:27 PM
AxoGen, Inc (AXGN) Receives Average Rating of "Buy" from BrokeragesAxoGen, Inc (AXGN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 26 at 9:53 AM
AxoGen (AXGN) & Its Peers Critical AnalysisAxoGen (AXGN) & Its Peers Critical Analysis
www.americanbankingnews.com - April 25 at 5:20 AM
AxoGen (AXGN) Set to Announce Earnings on MondayAxoGen (AXGN) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 23 at 9:20 AM
AxoGen (AXGN) & Its Competitors Head-To-Head AnalysisAxoGen (AXGN) & Its Competitors Head-To-Head Analysis
www.americanbankingnews.com - April 22 at 7:06 PM
AxoGen, Inc. to Report First Quarter 2018 Financial Results and Host Conference Call on April 30, 2018AxoGen, Inc. to Report First Quarter 2018 Financial Results and Host Conference Call on April 30, 2018
finance.yahoo.com - April 18 at 9:29 AM
AxoGen, Inc. to Report First Quarter 2018 Financial Results  and Host Conference Call on April 30, 2018AxoGen, Inc. to Report First Quarter 2018 Financial Results and Host Conference Call on April 30, 2018
feeds.benzinga.com - April 18 at 7:52 AM
Zacks: Brokerages Expect AxoGen, Inc (AXGN) Will Post Quarterly Sales of $17.21 MillionZacks: Brokerages Expect AxoGen, Inc (AXGN) Will Post Quarterly Sales of $17.21 Million
www.americanbankingnews.com - April 18 at 3:58 AM
AxoGen, Inc (AXGN) Expected to Announce Earnings of -$0.11 Per ShareAxoGen, Inc (AXGN) Expected to Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - April 16 at 9:21 AM

SEC Filings

AxoGen (NASDAQ:AXGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AxoGen (NASDAQ:AXGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AxoGen (NASDAQ AXGN) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.